Phathom Pharmaceuticals, Inc.
PHAT
$12.56
$0.030.24%
NASDAQ
| 03/31/2026 | 12/31/2025 | 09/30/2025 | 06/30/2025 | 03/31/2025 | |
|---|---|---|---|---|---|
| Revenue | 150.30% | 216.93% | 460.30% | 1,049.81% | 3,055.71% |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 150.30% | 216.93% | 460.30% | 1,049.81% | 3,055.71% |
| Cost of Revenue | 173.91% | 183.46% | 333.92% | 658.41% | 1,800.67% |
| Gross Profit | 146.53% | 222.57% | 485.20% | 1,146.76% | 3,427.64% |
| SG&A Expenses | -25.96% | -3.77% | 13.67% | 52.36% | 100.28% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | -18.13% | 0.71% | 14.79% | 45.80% | 75.53% |
| Operating Income | 66.27% | 42.34% | 25.86% | -6.41% | -38.22% |
| Income Before Tax | 54.51% | 33.82% | 19.12% | -11.12% | -40.21% |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | 54.51% | 33.82% | 19.12% | -11.12% | -40.21% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | 54.51% | 33.82% | 19.12% | -11.12% | -40.21% |
| EBIT | 66.27% | 42.34% | 25.86% | -6.41% | -38.22% |
| EBITDA | 66.38% | 42.40% | 25.90% | -6.43% | -38.28% |
| EPS Basic | 59.74% | 43.00% | 33.04% | 7.85% | -18.80% |
| Normalized Basic EPS | 59.75% | 43.00% | 33.03% | 7.85% | -18.80% |
| EPS Diluted | 59.74% | 43.00% | 33.04% | 7.85% | -18.80% |
| Normalized Diluted EPS | 59.75% | 43.00% | 33.03% | 7.85% | -18.80% |
| Average Basic Shares Outstanding | 13.35% | 15.46% | 20.94% | 21.26% | 20.48% |
| Average Diluted Shares Outstanding | 13.35% | 15.46% | 20.94% | 21.26% | 20.48% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |